Gelbard A S, Benua R S, Laughlin J S, Rosen G, Reiman R E, McDonald J M
J Nucl Med. 1979 Jul;20(7):782-4.
N-13 L-glutamate was used to image an osteogenic sarcoma in a 9-year-old patient. Serial quantitative measurements of the amount of N-13 taken up by the primary tumor showed a decrease of 40% after 10 wk of chemotherapy. Blood-clearance data obtained from normal subjects indicate that more than 90% of the N-13 activity had left the blood before scanning of the tumor was begun. It appears that the N-13 label concentrated in the soft-tissue portion of this osteogenic sarcoma, whereas Tc-99m diphosphonate uptake was greatest in the regions where calcification was occurring.
用N-13 L-谷氨酸对一名9岁骨肉瘤患者进行成像。对原发肿瘤摄取的N-13量进行系列定量测量显示,化疗10周后减少了40%。从正常受试者获得的血液清除数据表明,在开始扫描肿瘤之前,超过90%的N-13活性已从血液中清除。看来N-13标记物集中在该骨肉瘤的软组织部分,而锝-99m二膦酸盐摄取在发生钙化的区域最大。